June 9 (Reuters) – British drugmaker GSK on Tuesday agreed to acquire U.S.-listed cancer drug developer Nuvalent for $10.6 billion to boost its lung cancer portfolio. The all-cash deal values Nuvalent
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
THE REUTERS DAYBOOK Sunday, July 26, 2026 ----- The daybook editor is Timothy Ryan (reachable…
UPDATE 2-Kyiv hit with missiles; Russia and Ukraine both report civilians killed in strikes
(Updates with Kharkiv, Zaporizhzhia and Donetsk region attacks) July 26 (Reuters) - The Ukrainian capital…
Ugandan diplomat Otunnu joins race to become next UN head
* Uganda's Olara Otunnu bids to succeed Antonio Guterres * Seven contenders now in the…
